Authors: FLEMING TR NEATON JD GOLDMAN A DEMETS DL LAUNER C KORVICK J ABRAMS D BEERS D LOVELESS K MARTINEZ N MESARD CA REVES RR ROUFF JA KLEIN T MCDONALD R SLOTTEN R BROSGART C DREW L FESSEL J HUDSON R LOPEZ C THOMPSON S KUMI JO MASTROPOLAK D SARAVOLATZ LD KERKERING TM HIGGINSON RA GERNON L BAR M MENDEZ D ERNST J SCOTT J FINLEY B WARD D WISNIEWSKI T BRANDON W WALTER J CALHOUN C EBRIGHT JR SCHUMAN P BINCSIK A SWANSON K WINSLOW D SHERIDAN A TAYLOR V PEREZ G ELSADR W GUITY C JULEAU J SALVATI S DOWLING C SALVADOR GI BURNS AJ LAM SH CHILDRESS JF DEETS DL FLEMING TR MEYER KH POLLARD RB OFALLON JR RAHAL JJ WALTERS L WHITNEYWILLIAMS P WHITLEY RJ

Citation: Tr. Fleming et al., INSIGHTS FROM MONITORING THE CPCRA DIDANOSINE ZALCITABINE TRIAL, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 9-18